What drove the intraday fall in NWRN.SW stock today?

The intraday fall to **CHF16.50** (-5.71%) was driven by pre-earnings positioning ahead of Newron’s 24 March report and modest volume. Traders trimmed exposure to avoid event risk that could widen intraday swings.

What is Meyka AI's price forecast and implied return for NWRN.SW stock?

Meyka AI's forecast model projects **CHF23.38** in 12 months, implying **+41.70%** from **CHF16.50**. This is a model projection and not a guarantee; outcomes depend on earnings and clinical updates.

Which fundamentals should I watch for NWRN.SW analysis before earnings?

Focus on EPS (TTM **1.23**), operating cash flow per share (**1.23**), revenue per share (**2.9998**), and guidance on Xadago and pipeline assets. Watch liquidity and any partner or regulatory commentary.

Is NWRN.SW stock technically oversold and likely to bounce?

Technicals show **RSI 29.03** and oversold oscillators, suggesting a bounce is possible. However, earnings outcomes can extend the selloff, so technical recovery depends on event-driven news.

CH Stocks

-5.71% intraday: NWRN.SW Newron (SIX) Mar 2026 earnings risk may spark moves

ByDanny Kontos March 13, 2026March 13, 2026

NWRN.SW stock fell 5.71% intraday to CHF16.50 as traders reacted to pre-earnings positioning ahead of the company’s 24 March announcement. The move follows a one-day drop of CHF1.00 from a previous close of CHF17.50 and comes while average 50-day price sits at CHF21.43 and 200-day at CHF14.12. Volume is moderate at 95,346 shares versus an average of 154,444, signalling selective selling. We examine catalysts, valuation, and technical signals that explain why Newron Pharmaceuticals S.p.A. (NWRN.SW) is among the top intraday losers on the SIX in Switzerland.